Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children31410.24287/1726-1708-2020-19-1-116-121LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫHyperleucocytosis in children with acute mieloid leukemiaГиперлейкоцитоз у детей с острым миелоидным лейкозомZacharovN. V.ЗахаровН. В.
Russian Federation

Krasnoyarsk

Красноярск

https://orcid.org/0000-0002-0813-5626KalininaI. I.КалининаИ. И.
Russian Federation

MD, Pediatrician Hematologist, Department of Pediatric Hematology/Oncology,

117997, Moscow, Samory Mashela st., 1

врач-гематолог отделения детской гематологии/ онкологии,

117997, Москва, ГСП-7, ул. Саморы Машела, 1 

irina.kalinina@fccho-moscow.ruhttps://orcid.org/0000-0002-0183-1530VenevD. A.ВенёвД. А.
Russian Federation

Москва

https://orcid.org/0000-0002-2958-1705SalimovaT. Y.СалимоваТ. Ю.
Russian Federation

Москва

https://orcid.org/0000-0001-8610-0624EvseevD. A.ЕвсеевД. А.
Russian Federation

Москва

https://orcid.org/0000-0001-8571-5395GoronkovaO. V.ГоронковаО. В.
Russian Federation

Москва

https://orcid.org/0000-0002-0016-6698MaschanA. A.МасчанА. А.
Russian Federation

Москва

Krasnoyarsk Clinical Center of maternity and childhoodКГБУ «Красноярский краевой клинический центр охраны матери и детства» Минздрава РоссииDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России280320201911161212803202028032020Copyright ©; 2020, «D. Rogachev NMRCPHOI»Copyright ©; 2020, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2020«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/314

This article presents analysis of recent publications on hyperleukocytosis in children with AML. The mechanisms of the development of life-threatening complications accompanying hyperleukocytosis are analyzed in detail. In this review of the literature, the authors focus on the adequacy and timing of therapy for such life-threatening complications of hyperleukocytosis as leukostasis, DIC, and acute tumor lysis syndrome. The authors emphasize that in the treatment of hyperleukocytosis an important place, in addition to specific therapy, is taken by the accompanying therapy in the intensive care unit. The place of replacement blood transfusions and leukopheresis as part of the accompanying therapy is discussed.

Статья представляет собой анализ последних публикаций, посвященных гиперлейкоцитозу при остром миелоидном лейкозе у детей. Подробно рассмотрены механизмы развития жизнеугрожающих осложнений, сопровождающих гиперлейкоцитоз. В данном обзоре литературы авторы акцентируют внимание на адекватности и сроках проведения терапии таких жизнеугрожающих осложнений гиперлейкоцитоза, как лейкостаз, ДВС-синдром, синдром острого лизиса опухоли. Авторы подчеркивают, что в лечении гиперлейкоцитоза важное место, помимо специфической терапии, занимает сопроводительная терапия в условиях отделения интенсивной терапии. Обсуждается место заменных гемотрансфузий и лейкофереза в составе сопроводительной терапии.

childrenacute myeloid leukemiachemotherapyдетиострый миелоидный лейкозгиперлейкоцитозхимиотерапия1. McKee L.C., Collins R.D. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Med (United States). 1974.McKee L.C., Collins R.D. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Med (United States). 1974.2. Lichtman M.A., Rowe J.M. Hyperleukocytic Leukemias: Rheological, Clinical, and Therapeutic Considerations. Blood 1982; 60: 279–83.Lichtman M.A., Rowe J.M. Hyperleukocytic Leukemias: Rheological, Clinical, and Therapeutic Considerations. Blood 1982; 60: 279–83.3. Chim C.S., Ooi C. The irreplaceable image. Haematologica 2001; 86: 1231.Chim C.S., Ooi C. The irreplaceable image. Haematologica 2001; 86: 1231.4. Kaminsky D.A., Hurwitz C.G., Olmstead J.I. Pulmonary leukostasis mimicking pulmonary embolism. Leuk Res 2000. DOI: 10.1016/S0145-2126(99)00162-9Kaminsky D.A., Hurwitz C.G., Olmstead J.I. Pulmonary leukostasis mimicking pulmonary embolism. Leuk Res 2000. DOI: 10.1016/S0145-2126(99)00162-95. Stucki A., Rivier A.S., Gikic M., Monai N., Schapira M., Spertini O. Endothelial cell activation by myeloblasts: Molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001; 97 (7): 2121–9.Stucki A., Rivier A.S., Gikic M., Monai N., Schapira M., Spertini O. Endothelial cell activation by myeloblasts: Molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001; 97 (7): 2121–9.6. Röllig C., Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood 2015; 125 (21): 3246–52.Röllig C., Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood 2015; 125 (21): 3246–52.7. Creutzig U., Ritter J., Budde M., Sutor A., Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 1987; 60 (12): 3071–9.Creutzig U., Ritter J., Budde M., Sutor A., Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 1987; 60 (12): 3071–9.8. Würthner J.U., Köhler G., Behringer D., Lindemann A., Mertelsmann R., Lübbert M. Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis: A clinicopathologic report of four cases. Cancer 1999; 85 (2): 368–74.Würthner J.U., Köhler G., Behringer D., Lindemann A., Mertelsmann R., Lübbert M. Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis: A clinicopathologic report of four cases. Cancer 1999; 85 (2): 368–74.9. Campana D., Pui C.H. Childhood Leukemia. In: Abeloff’s Clinical Oncology: Fifth Edition 2014; 1849–72.e11.Campana D., Pui C.H. Childhood Leukemia. In: Abeloff’s Clinical Oncology: Fifth Edition 2014; 1849–72.e11.10. Steeber D.A., Campbell M.A., Basit A., Ley K., Tedder T.F. Optimal selectin-mediated rolling of leukocytes during inflammation in vivo requires intercellular adhesion molecule-1 expression. Proc Natl Acad Sci 1998; 95 (13): 7562–7. DOI: 10.1073/pnas.95.13.7562Steeber D.A., Campbell M.A., Basit A., Ley K., Tedder T.F. Optimal selectin-mediated rolling of leukocytes during inflammation in vivo requires intercellular adhesion molecule-1 expression. Proc Natl Acad Sci 1998; 95 (13): 7562–7. DOI: 10.1073/pnas.95.13.756211. Vestweber D., Blanks J.E. Mechanisms That Regulate the Function of the Selectins and Their Ligands. Physiol Rev 1999. DOI: 10.1152/physrev.1999.79.1.181Vestweber D., Blanks J.E. Mechanisms That Regulate the Function of the Selectins and Their Ligands. Physiol Rev 1999. DOI: 10.1152/physrev.1999.79.1.18112. Kansas G.S. Selectins and their ligands: current concepts and contreoversies. Blood 1996; 88: 3259–87.Kansas G.S. Selectins and their ligands: current concepts and contreoversies. Blood 1996; 88: 3259–87.13. Lowenberg B., Downing J.R., Burnett A. Acute Myeloid Leukemia. N Engl J Med 1999 Sep; 341 (14): 1051–62.Lowenberg B., Downing J.R., Burnett A. Acute Myeloid Leukemia. N Engl J Med 1999 Sep; 341 (14): 1051–62.14. Extermann M., Bacchi M., Monai N., Fopp M., Fey M., Tichelli A., et al. Relationship Between Cleaved L-Selectin Levels and the Outcome of Acute Myeloid Leukemia. Blood 1998; 92: 3115–22.Extermann M., Bacchi M., Monai N., Fopp M., Fey M., Tichelli A., et al. Relationship Between Cleaved L-Selectin Levels and the Outcome of Acute Myeloid Leukemia. Blood 1998; 92: 3115–22.15. Byrd J.C., Weiss R.B., Arthur D.C. Lawrence D., Baer M.R., Davey F. et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): Results from Cancer and Leukemia Group B 8461. J Clin Oncol 1997; 15 (2): 466–75.Byrd J.C., Weiss R.B., Arthur D.C. Lawrence D., Baer M.R., Davey F. et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): Results from Cancer and Leukemia Group B 8461. J Clin Oncol 1997; 15 (2): 466–75.16. Ganzel C., Becker J., Mintz P.D., Lazarus H.M., Rowe J.M. Hyperleukocytosis, leukostasis and leukapheresis: Practice management. Blood Rev 2012; 26 (3): 117–22.Ganzel C., Becker J., Mintz P.D., Lazarus H.M., Rowe J.M. Hyperleukocytosis, leukostasis and leukapheresis: Practice management. Blood Rev 2012; 26 (3): 117–22.17. Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009; 145 (1): 24–33.Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009; 145 (1): 24–33.18. Porcu P., Cripe L., Ng E., Bhatia S., Danielson C., Orazi A., et al. Hyperleukocytic leukemias and leukostasis: A review of pathophysiology, clinical presentation and management. Leukemia and Lymphoma 2000; DOI: 10.3109/10428190009053534Porcu P., Cripe L., Ng E., Bhatia S., Danielson C., Orazi A., et al. Hyperleukocytic leukemias and leukostasis: A review of pathophysiology, clinical presentation and management. Leukemia and Lymphoma 2000; DOI: 10.3109/1042819000905353419. Coiffier B., Altman A., Pui C.H., Younes A., Cairo M.S. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 2008; 26 (16): 2767–78.Coiffier B., Altman A., Pui C.H., Younes A., Cairo M.S. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 2008; 26 (16): 2767–78.20. Darmon M., Guichard I., Vincent F. Rasburicase and tumor lysis syndrome: Lower dosage, consideration of indications, and hyperhydration. J Clin Oncol 2011; 29 (3): e67-e68, author replye 69.Darmon M., Guichard I., Vincent F. Rasburicase and tumor lysis syndrome: Lower dosage, consideration of indications, and hyperhydration. J Clin Oncol 2011; 29 (3): e67-e68, author replye 69.21. Bunin N.J., Pui C.H. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3 (12): 1590–5.Bunin N.J., Pui C.H. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3 (12): 1590–5.22. Hatfield K.J., Reikvam H., Bruserud O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem 2010; 17 (36): 4448–61.Hatfield K.J., Reikvam H., Bruserud O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem 2010; 17 (36): 4448–61.23. Hatfield K.J., Bedringsaas S.L., Ryningen A., Gjertsen B.T., Bruserud О. Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur Cytokine Netw 2010; 21 (3): 154–64.Hatfield K.J., Bedringsaas S.L., Ryningen A., Gjertsen B.T., Bruserud О. Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur Cytokine Netw 2010; 21 (3): 154–64.24. Paupert J., De Mas V.M., Demur C., Salles B., Muller C. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 2008; 7 (8): 1047–53.Paupert J., De Mas V.M., Demur C., Salles B., Muller C. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 2008; 7 (8): 1047–53.25. Porcu P., Farag S., Marcucci G., Cataland S.R., Kennedy M.S., Bissell M. Leukocytoreduction for acute leukemia. Ther Apher 2002; 1: 15–23.Porcu P., Farag S., Marcucci G., Cataland S.R., Kennedy M.S., Bissell M. Leukocytoreduction for acute leukemia. Ther Apher 2002; 1: 15–23.26. Robak T., Wrzesien-Kus A., Lech-Maranda E., Kowal M., Dmoszynska A. Combination regimen of cladribine (2-Chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2000; 1–2: 121–9.Robak T., Wrzesien-Kus A., Lech-Maranda E., Kowal M., Dmoszynska A. Combination regimen of cladribine (2-Chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2000; 1–2: 121–9.27. Krance R.A. Krance R.A., Hurwitz C.A., Head D.R., Raimondi S.C., Behm F.G., et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001; 11: 2804–11.Krance R.A. Krance R.A., Hurwitz C.A., Head D.R., Raimondi S.C., Behm F.G., et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001; 11: 2804–11.28. De Botton S., Dombret H., Sanz M., San Miguel J., Caillot D., Zittoun R. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712–8.De Botton S., Dombret H., Sanz M., San Miguel J., Caillot D., Zittoun R. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712–8.29. Adès L., Guerci A., Raffoux E., Sanz M., Chevallier P., Lapusan S., et al. Very long-term outcome of acute promyelocytic leukemia after treatment with alltrans retinoic acid and chemotherapy: The European APL Group experience. Blood 2010; 115: 1690–6.Adès L., Guerci A., Raffoux E., Sanz M., Chevallier P., Lapusan S., et al. Very long-term outcome of acute promyelocytic leukemia after treatment with alltrans retinoic acid and chemotherapy: The European APL Group experience. Blood 2010; 115: 1690–6.30. Azoulay É., Canet E., Raffoux E., Lengline E., Lemiale V., Vincent F., et al. Dexamethasone in patients with acute lung injury from acute monocytic leukaemia. Eur Respir J 2012; 39 (3): 648–53.Azoulay É., Canet E., Raffoux E., Lengline E., Lemiale V., Vincent F., et al. Dexamethasone in patients with acute lung injury from acute monocytic leukaemia. Eur Respir J 2012; 39 (3): 648–53.31. Meduri G., Headley A., Golden E., Carson S., Umberger R., Kelso T., Tolley E. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. J Am Med Assoc 1998; 280: 159–65.Meduri G., Headley A., Golden E., Carson S., Umberger R., Kelso T., Tolley E. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. J Am Med Assoc 1998; 280: 159–65.32. Mercat A., Diehl J., Michard F., Anguel N., Teboul J., Labrousse J., et al. Extending inspiratory time in acute respiratory distress syndrome. Crit Care Med 2001; 29 (1): 40–4.Mercat A., Diehl J., Michard F., Anguel N., Teboul J., Labrousse J., et al. Extending inspiratory time in acute respiratory distress syndrome. Crit Care Med 2001; 29 (1): 40–4.33. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. – М.: Медпрактика-М, 2009.Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. – М.: Медпрактика-М, 2009.34. Holig K., Moog R. Leukocyte depletion by therapeutic leukocytapheresis in patients with leukemia. Transfusion Medicine and Hemotherapy 2012; 39 (4): 241–5.Holig K., Moog R. Leukocyte depletion by therapeutic leukocytapheresis in patients with leukemia. Transfusion Medicine and Hemotherapy 2012; 39 (4): 241–5.35. Bruserud O., Liseth K., Stamnesfet S., Cacic D.L., Melve G., Kristoffersen E., et al. Hyperleukocytosis and leukocytapheresis in acute leukaemias: Experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfus Med 2013; 23 (6): 397–406.Bruserud O., Liseth K., Stamnesfet S., Cacic D.L., Melve G., Kristoffersen E., et al. Hyperleukocytosis and leukocytapheresis in acute leukaemias: Experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfus Med 2013; 23 (6): 397–406.36. Pastore F., Pastore A., Wittmann G., Hiddemann W., Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One, 2014; 9(4): e95062.Pastore F., Pastore A., Wittmann G., Hiddemann W., Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One, 2014; 9(4): e95062.37. Oberoi S., Lehrnbecher Th., Phillips B., Hitzler J., Ethier M.-C., Beyene J., et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and meta-analysis. Leuk Res 2014; 38 (4): 460–8.Oberoi S., Lehrnbecher Th., Phillips B., Hitzler J., Ethier M.-C., Beyene J., et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and meta-analysis. Leuk Res 2014; 38 (4): 460–8.